

Supplementary Table 2. Cox regression analysis of factors associated with TTP before and after IPTW

Variable	Before IPTW				After IPTW			
	Crude HR (95% CI)	P-value	Adjusted HR (95% CI)	P-value	Crude HR (95% CI)	P-value	Adjusted HR (95% CI)	P-value
Treatment		0.56		0.75		0.49		0.57
Lenvatinib	1*		1*		1*		1*	
Atezolizumab plus bevacizumab	0.82 (0.43-1.58)		0.90 (0.45-1.78)		0.79 (0.42-1.52)		0.83 (0.44-1.58)	
Age (years)		0.54				0.47		
<65	1*				1*			
≥65	0.81 (0.41-1.60)				0.77 (0.38-1.56)			
Sex		0.46				0.32		
Female	1*				1*			
Male	1.36 (0.60-3.10)				1.46 (0.70-3.05)			
Etiology of HCC		0.16				0.06		
Other etiology	1*				1*			
HBV or HCV	0.50 (0.19-1.31)				0.52 (0.27-1.02)			
Esophageal varix		0.89				0.89		
Absent	1*				1*			
Present	1.05 (0.55-1.99)				0.96 (0.51-1.78)			
Child-Pugh score		0.15		0.03		0.19		
A5	1*				1*			
A6	1.63 (0.84-3.17)				1.53 (0.81-2.90)			
AFP (ng/mL)		0.09				0.09		
<200	1*				1*			
≥200	1.83 (0.91-3.71)				1.74 (0.92-3.28)			
PIVKA-II (mAU/mL)		0.30				0.31		
<1,000	1*				1*			
≥1,000	1.41 (0.74-2.70)				1.39 (0.74-2.59)			
Number of hepatic masses		0.93				0.86		
Single	1*				1*			
Multiple	1.03 (0.53-2.01)				0.94 (0.49-1.90)			
LN metastasis		0.32				0.28		
Absent	1*				1*			
Present	0.63 (0.26-1.55)				0.61 (0.24-1.51)			
Extrahepatic metastasis		0.53				0.80		
Absent	1*				1*			
Present	1.23 (0.64-2.35)				1.09 (0.58-2.05)			
Extent of PVTT		0.45				0.43		0.49
No main PV invasion	1*		1*		1*		1*	
Main PV invasion	1.34 (0.63-2.86)		1.38 (0.63-2.99)		1.30 (0.68-2.50)		1.25 (0.67-2.32)	
Hepatic vein invasion		0.34				0.20		
Absent	1*				1*			
Present	1.67 (0.58-4.75)				1.54 (0.79-3.01)			

TTP, time-to-progression; IPTW, inverse probability of treatment weighting; HR, hazard ratio; CI, confidence interval; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, alpha-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-II; LN, lymph node; PVTT, portal vein tumor thrombosis; PV, portal vein.

*Reference.